- Clinical Trials
- January 2024
- 60 Pages
Global
From €1216EUR$1,250USD£1,042GBP
- Report
- March 2024
- 192 Pages
Global
From €3283EUR$3,374USD£2,812GBP
€3648EUR$3,749USD£3,125GBP
- Report
- April 2024
- 197 Pages
Global
From €4816EUR$4,950USD£4,126GBP
- Report
- February 2024
- 180 Pages
Global
From €4768EUR$4,900USD£4,084GBP
- Report
- November 2023
- 190 Pages
Global
From €4768EUR$4,900USD£4,084GBP
- Report
- March 2024
- 200 Pages
Global
From €4038EUR$4,150USD£3,459GBP
- Report
- January 2023
- 143 Pages
Global
From €2431EUR$2,499USD£2,083GBP
- Report
- April 2023
- 112 Pages
Global
From €4622EUR$4,750USD£3,959GBP
- Report
- March 2024
- 159 Pages
From €7735EUR$7,950USD£6,626GBP
- Report
- September 2019
Asia Pacific
From €5225EUR$5,370USD£4,476GBP
The Aldosterone Antagonist market is a subset of the Cardiovascular Drugs market. Aldosterone antagonists are drugs used to treat hypertension, heart failure, and other cardiovascular conditions. These drugs work by blocking the action of aldosterone, a hormone that can cause the body to retain sodium and water, leading to an increase in blood pressure. Aldosterone antagonists are often used in combination with other drugs to treat hypertension and heart failure.
The Aldosterone Antagonist market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Merck & Co., Novartis, Pfizer, Sanofi, and AstraZeneca. Other companies in the market include Daiichi Sankyo, Boehringer Ingelheim, and Takeda Pharmaceuticals. Show Less Read more
